BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31782256)

  • 21. High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy, independently of tumor size.
    Ulger S; Demirci NY; Eroglu FN; Cengiz HH; Tunc M; Tatci E; Yilmaz U; Cetin E; Avci E; Cengiz M
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):495-502. PubMed ID: 24474555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy.
    Huang W; Liu B; Fan M; Zhou T; Fu Z; Zhang Z; Li H; Li B
    Eur J Radiol; 2015 Mar; 84(3):482-488. PubMed ID: 25533718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
    Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
    Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic values of mid-radiotherapy
    Kim N; Cho H; Yun M; Park KR; Lee CG
    Radiat Oncol; 2019 Feb; 14(1):27. PubMed ID: 30717809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
    Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R
    Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
    PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
    Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
    Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer.
    Furukawa T; Miyata Y; Kushitani K; Mimae T; Tsutani Y; Takeshima Y; Okada M
    Jpn J Clin Oncol; 2015 Dec; 45(12):1154-61. PubMed ID: 26386467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
    Wu H; Dong S; Li X; Shi L; Shao D; Zhang Q; Chen M; Cao Y; Thant M; Huang X
    Lung Cancer; 2020 Feb; 140():80-86. PubMed ID: 31901595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
    Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A
    Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Predictive Value of Early In-Treatment
    Usmanij EA; Natroshvili T; Timmer-Bonte JNH; Oyen WJG; van der Drift MA; Bussink J; Geus-Oei LF
    J Nucl Med; 2017 Aug; 58(8):1243-1248. PubMed ID: 28336778
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.
    Li L; Hu M; Zhu H; Zhao W; Yang G; Yu J
    Clin Lung Cancer; 2010 Sep; 11(5):335-40. PubMed ID: 20837459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
    Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.
    Hellwig D; Graeter TP; Ukena D; Georg T; Kirsch CM; Schäfers HJ
    J Thorac Cardiovasc Surg; 2004 Dec; 128(6):892-9. PubMed ID: 15573074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy.
    Moon SH; Cho SH; Park LC; Ji JH; Sun JM; Ahn JS; Park K; Choi JY; Ahn MJ
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1005-13. PubMed ID: 23595109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.